Plaintiffs file second amended US complaint against Biogen over Tecfidera
MLex Summary: Plaintiffs filed a second amended US class action accusing Biogen of unlawfully impairing competition from generic versions of its brand-name prescription drug Tecfidera, which is used to treat multiple...To view the full article, register now.
Already a subscriber? Click here to view full article